Brain

The Rush for Non-Addictive Painkillers to Counter the Opioid Crisis Puts Two Companies Close to FDA Decisions

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding…

1 year ago

Achieve Life Sciences Strengthens Leadership with Appointment of Dr. Mark Rubinstein, Nicotine Dependence Expert, as New Head of Medical Affairs

SEATTLE and VANCOUVER, British Columbia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical…

1 year ago

Aligos Therapeutics Appoints David Perry as Vice President of Business Development

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company…

1 year ago

AlzeCure’s Abstract on ACD856’s Anti-inflammatory Effects to be Presented at a Leading Alzheimer’s Conference

STOCKHOLM, SWEDEN / ACCESSWIRE / October 1, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical…

1 year ago

ZEISS introduces its latest Robotic Visualisation System for neuro surgery

With best digital visualization and seamless robotic interactions, ZEISS KINEVO 900 S is representing a (r)evolution in the market. JENA,…

1 year ago

Cortechs.ai Announces Strategic Partnership with Ascend Imaging to Expand Access to Cutting-Edge Radiology Solutions

SAN DIEGO, Sept. 30, 2024 /PRNewswire/ -- Cortechs.ai, a leader in advanced imaging software medical analysis, is proud to announce…

1 year ago

Avalyn Announces Upcoming Presentations on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the 22nd International Colloquium on Lung and Airway Fibrosis

CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled…

1 year ago

Helius Medical Technologies, Inc. Announces Positive Preliminary Results of the PoNSTEP Study

-- Achieves primary endpoint showing a linear relationship between adherence to PoNS Therapy® in Phase 2 and improvement in DGI…

1 year ago